Bone and Join Infection (BJI), Periprosthetic Joint Infection (PJI)
Conditions
Keywords
BJI, Staphylococcus aureus, biomarkers
Brief summary
There are more than one million (\> 40,000 cases per year in France) of osteoarticular infections (OAI) yearly in the world. The number of these infections is constantly increasing due to an increase in life expectancy associated with an increase in prosthesis fitting, as well as an increase in comorbid factors. These are severe pathologies associated with mortality (5%) and significant morbidity (40%), responsible for functional sequelae with an individual cost (prolonged hospitalization, altered quality of life, disability) and societal (sick leave, partial disability). or total, temporary or permanent) extremely high. In addition, reinfection rates within two years of treatment are high. The BJIs are a group of clinical entities that have in common the invasion and progressive destruction of bone and cartilage tissue by bacterial-like microorganisms. Staphylococcus spp is the main pathogen (\>50%) in BJI and is associated with particularly difficult to treat infections, with a high rate of chronicity and relapses, especially in case of implanted material. The difficulty in managing these infections is partly linked, on the one hand, to the fact that the pathogens are in persistent metabolic forms and in intracellular reservoirs which make them insensitive to conventional antibiotics and, on the other hand, the absence of reliable markers of the infection and above all of its clinical resolution, which complicates clinical trials. ESPRI-IOAC is a consortium of 4 partners (private-public) from Lyon area and which aims at: * studying the translational value of BJI preclinical models * identifying biomarkers of infection in preclinical models and at assessing them in a prospective study. The current study is part of the global ESPRI-IOAC consortium, and represent the clinical application. It is a prospective study of patients treated for BJI in the infectious disease department of the Hospices Civils de Lyon, La Croix-Rousse, for osteo-articular infections due to Staphylococcus aureus, or for simple mechanical revision or for cruciate ligament surgery, the objective of which is to highlight biomarkers of interest in the diagnosis of chronic BJI and, or predictive of the therapeutic response. The translational value of the experimental models used in the BJI will also be studied.
Interventions
OTHERConstitution of serum bank at D0
Blood samples at Day 0 (day of surgery)
OTHERConstitution of serum bank during follow-up
Blood samples are obtained at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years.
OTHERELISA assays of serum markers of bone remodeling at D0
Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at Day 0 (day of surgery)
OTHERELISA assays of serum markers of bone remodeling during follow-up
Assessment by ELISA assays of serum markers of bone remodelling: the osteocalcin (OC), the procollagen propeptide type 1 (PINP), the cross linked telopeptide of type 1 collagen (CTX1) and the periostin at week 2, week 6 post-surgery, at the end of antibiotherapy and 6 months post-surgery, only for patients with staphylococcus aureus monoinfection who are follow-up during two years
OTHERAnalysis of bacterial gene expression at D0
Assessement of bacterial gene expression on surgery residual tissue (bone tissue, joint fluid, fragment of prostheses) collected at Day 0 (day of the surgery)
Sponsors
Hospices Civils de Lyon
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 30 years old * Hospitalized in orthopedic surgery for one of these reasons: * A suspected infection or a documented proven infection with staphylococcus aureus on prosthesis or other orthopedic implant * A mechanical cause (absence of infection) on prosthesis or orthopedic implant * Documented chronic osteomyelitis due to staphylococcus aureus * Cruciate ligament surgery * Patient not subject to any legal protection measure * Patient who can be followed in the Infectious and Tropical Diseases Department, CRIOAC Lyon (Centre de Référence des Infections Ostéo-Articulaires complexes = reference centre of bone and joint infections in french), La Croix-Rousse for at least 6 months post-surgery * Patient who gave his no-opposition * Patient giving his consent to the creation of biological collections
Exclusion criteria
* Polymicrobial infection * Known inflammatory disease * Hyperthyroidism * Cushing's disease * Osteomalacia * Renal osteodystrophy * Paget's disease * Malignant disease in progress * Multiple myeloma * Bone metastases * Ehlers-Danlos syndrome * Pregnant or lactating woman * Renal impairment (Creatinine clearance \<60 mL / min) * Trauma in the 6 months preceding surgery * Fracture in the 6 months preceding surgery * Corticosteroid therapy in progress at the time of inclusion * Active infection with HIV (human immunodeficiency virus), HBV (hepatitis B virus), HCV hepatitis C virus) documented in the patient file * Antibiotic treatment in the 15 days preceding inclusion * People placed under judicial protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dosages of serum osteocalcin | At the time of surgery | Comparison of dosages by ELISA test of serum osteocalcin between the patients with OAI and the control patients without OAI at the time of inclusion in order to demonstrate a marker or a combination of markers for OAI. |
| Dosages of serum procollagen propeptide type 1 | At the time of surgery | Comparison of dosages by ELISA test of serum procollagen propeptide type 1 between the patients with OAI and the control patients without OAI at the time of inclusion in order to demonstrate a marker or a combination of markers for OAI. |
| Dosages of serum cross-linked telopeptide of type 1 collagen | At the time of surgery | Comparison of dosages by ELISA test of serum cross-linked telopeptide of type 1 collagen between the patients with OAI and the control patients without OAI at the time of inclusion in order to demonstrate a marker or a combination of markers for OAI. |
| Dosages of serum periostin | At the time of surgery | Comparison of dosages by ELISA test of serum periostin between the patients with OAI and the control patients without OAI at the time of inclusion in order to demonstrate a marker or a combination of markers for OAI. |
Countries
France
Outcome results
None listed